AI assistant
Sending…
Indaptus Therapeutics, Inc. — Director's Dealing 2021
Aug 2, 2021
35475_dirs_2021-08-02_8202ef4d-1451-4f4a-a3eb-e91af259ff0f.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 3 — Initial Statement of Beneficial Ownership
Issuer: Intec Parent Inc. (NTEC)
CIK: 0001857044
Period of Report: 2021-07-23
Reporting Person: Meckler Jeffrey A (Director, Chief Executive Officer)
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock | 2460 | Direct |
Holdings (Derivative)
| Security | Exercise Price | Expiration | Underlying | Shares | Ownership |
|---|---|---|---|---|---|
| Stock Option (right to buy) | $425.6 | 2027-04-10 | Common Stock (1500) | Direct | |
| Stock Option (right to buy) | $425.6 | 2027-05-01 | Common Stock (813) | Direct | |
| Stock Option (right to buy) | $536.0 | 2027-12-11 | Common Stock (4750) | Direct | |
| Stock Option (right to buy) | $355.2 | 2025-06-28 | Common Stock (1250) | Direct | |
| Stock Option (right to buy) | $611.2 | 2026-04-04 | Common Stock (1563) | Direct | |
| Stock Option (right to buy) | $24.6 | 2027-07-15 | Common Stock (3750) | Direct |
Footnotes
F1: The stock options are fully vested and are exercisable.
F2: The options vest over a period of three years from April 4, 2019, 33.3% on the first anniversary of such date and 8.33% every three months thereafter, ending April 4, 2022.
F3: The options vest over a period of three years from July 15, 2020, 33.3% on the first anniversary of such date and 8.33% every three months thereafter, ending July 15, 2023.
More from Indaptus Therapeutics, Inc.
Interim / Quarterly Report
2026
May 15
Report Publication Announcement
2026
May 15
Board/Management Information
2026
Apr 23
Board/Management Information
2026
Apr 3
Director's Dealing
2026
Mar 24
Director's Dealing
2026
Feb 27
Regulatory Filings
2026
Feb 27
Director's Dealing
2026
Feb 13
Capital/Financing Update
2026
Feb 12
Director's Dealing
2026
Jan 23